[ad_1]
A new treatment for chronic hepatitis C with the drug Vosevi will be reimbursed from the basic package starting July 1, 2018. This was decided by Minister Bruno Bruins (Medical Care) after negotiating with the manufacturer on the price of the new drug. Vosevi can be used in all patients with chronic hepatitis C. With the inclusion of Vosevi, all drugs for hepatitis C patients in the Netherlands are now available in basic packaging.
Chronic Hepatitis C
Chronic hepatitis C is a disease that in many cases only manifests itself after many years. in a small percentage also to liver cancer. Due to the high cost of new hepatitis C drugs, the Dutch Institute of Health Care has advised the Netherlands to opt for this group of drugs. negotiate with the manufacturer on the price. This is the eighth time that the reimbursement of a hepatitis C drug has been successfully negotiated: in total, financial arrangements have been made for 30 drugs. A 12-week treatment with Vosevi originally cost € 51,000. Due to the negotiations, this price is now lower. Due to the confidentiality of the agreements with the supplier, the outcome of the negotiations can not be made public. However, a global picture can be given. In 2015 and 2016, price negotiations with pharmaceutical companies resulted in a total savings of 155 million euros. The results for 2017 will be announced later this year.
Source link
